Paradigm Biopharmaceuticals Limited

ASX:PAR Stok Raporu

Piyasa değeri: AU$77.1m

Paradigm Biopharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Paradigm Biopharmaceuticals' CEO is Paul Rennie, appointed in Jan 2014, has a tenure of 10.83 years. total yearly compensation is A$1.10M, comprised of 86.5% salary and 13.5% bonuses, including company stock and options. directly owns 2.72% of the company’s shares, worth A$1.96M. The average tenure of the management team and the board of directors is 4.3 years and 4.1 years respectively.

Anahtar bilgiler

Paul Rennie

İcra Kurulu Başkanı

AU$1.1m

Toplam tazminat

CEO maaş yüzdesi86.5%
CEO görev süresi10.8yrs
CEO sahipliği2.7%
Yönetim ortalama görev süresi4.3yrs
Yönetim Kurulu ortalama görev süresi4.1yrs

Son yönetim güncellemeleri

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22
Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17
Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22
Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24
We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28
Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29
When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

CEO Tazminat Analizi

Paul Rennie'un ücretlendirmesi Paradigm Biopharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024AU$1mAU$948k

-AU$59m

Mar 31 2024n/an/a

-AU$64m

Dec 31 2023n/an/a

-AU$69m

Sep 30 2023n/an/a

-AU$60m

Jun 30 2023AU$2mAU$602k

-AU$52m

Mar 31 2023n/an/a

-AU$48m

Dec 31 2022n/an/a

-AU$44m

Sep 30 2022n/an/a

-AU$42m

Jun 30 2022AU$1mAU$219k

-AU$39m

Mar 31 2022n/an/a

-AU$40m

Dec 31 2021n/an/a

-AU$41m

Sep 30 2021n/an/a

-AU$37m

Jun 30 2021AU$1mAU$510k

-AU$34m

Mar 31 2021n/an/a

-AU$31m

Dec 31 2020n/an/a

-AU$28m

Sep 30 2020n/an/a

-AU$20m

Jun 30 2020AU$632kAU$462k

-AU$12m

Mar 31 2020n/an/a

-AU$14m

Dec 31 2019n/an/a

-AU$16m

Sep 30 2019n/an/a

-AU$16m

Jun 30 2019AU$1mAU$420k

-AU$16m

Mar 31 2019n/an/a

-AU$11m

Dec 31 2018n/an/a

-AU$7m

Sep 30 2018n/an/a

-AU$7m

Jun 30 2018AU$573kAU$380k

-AU$6m

Tazminat ve Piyasa: Paul's total compensation ($USD718.64K) is above average for companies of similar size in the Australian market ($USD299.27K).

Tazminat ve Kazançlar: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Rennie (65 yo)

10.8yrs

Görev süresi

AU$1,096,287

Tazminat

Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, served as Independent Non-Executive Chairman at NeuroScientific Biopharmaceuticals Limited since June 21, 2021 until November 23, 2022, was it...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Paul Rennie
Founder10.8yrsAU$1.10m2.72%
A$ 2.1m
Donna Skerrett
Chief Medical Officer and Executive Director2.3yrsAU$1.23m0.31%
A$ 240.7k
Abby Macnish Niven
Company Secretary & CFO2.3yrsVeri yokVeri yok
Ravi Krishnan
Chief Scientific Officer9.2yrsVeri yokVeri yok
Simon White
Director of Investor Relationsno dataVeri yokVeri yok
Michael Imperiale
Global Head of Drug Safety & MPS4.4yrsVeri yokVeri yok
Beverley Huttmann
Commercial Head4.1yrsVeri yokVeri yok
Michelle Coffey
Global Head of Regulatory Affairsno dataVeri yokVeri yok
Mukesh Ahuja
Global Clinical Head of OAno dataVeri yokVeri yok

4.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: PAR's management team is considered experienced (4.3 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Paul Rennie
Founder10.5yrsAU$1.10m2.72%
A$ 2.1m
Donna Skerrett
Chief Medical Officer and Executive Director4.3yrsAU$1.23m0.31%
A$ 240.7k
Amos Meltzer
Independent & Non-Executive Director3.9yrsAU$88.80kVeri yok
Matthew Fry
Independent Non-Executive Directorless than a yearAU$24.24k0.41%
A$ 312.4k

4.1yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PAR's board of directors are considered experienced (4.1 years average tenure).